文献速递妇产影像技术与安全US

早孕期联合筛查子痫前期:PAPP-A与PlGF的比较

Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-09-13

本研究基于早孕期联合筛查队列,回顾性比较PAPP-A与PlGF在筛查早产型子痫前期、足月型子痫前期、小于胎龄儿及21三体综合征中的性能。结果显示两者对子痫前期和小于胎龄儿的筛查性能无显著差异,提示在公共医疗环境下可沿用现有PAPP-A方案。

要点

  • 早孕期联合筛查子痫前期时,PAPP-A与PlGF的筛查性能无显著临床差异。
  • PlGF在子痫前期、小于胎龄儿及21三体妊娠中位数MoM均显著低于对照组。
  • 公共医疗环境下无需改变现有早孕期PAPP-A评估方案即可实施子痫前期联合筛查。

关键影像表现/征象

  • 子痫前期、小于胎龄儿及21三体妊娠的中位血清PlGF MoM均显著低于对照组。
  • 子痫前期组PlGF中位MoM为1.0(IQR 0.8-1.4),低于对照组1.2(IQR 0.9-1.5),P<0.01。
  • 小于胎龄儿组PlGF中位MoM为1.0(IQR 0.8-1.3),低于对照组,P<0.001。
  • 21三体组PlGF中位MoM为0.6(IQR 0.5-0.9),低于对照组,P<0.0001。

诊断标准与关键数值

  • 早产型子痫前期筛查AUC:PAPP-A组0.78 vs PlGF组0.79,P=0.55。
  • 足月型子痫前期筛查AUC:PAPP-A组0.74 vs PlGF组0.74,P=0.60。
  • 小于胎龄儿和21三体联合筛查的敏感度和特异度在PAPP-A与PlGF间无显著差异。

临床应用与阅片要点

  • 早孕期联合筛查子痫前期可继续使用PAPP-A,无需常规替换为PlGF。
  • 生物标志物选择应兼顾筛查性能与检测条件,根据机构情况决定。
  • 对高 preterm PE 风险(≥1/50)孕妇给予阿司匹林150mg/日,并在28和36周行胎儿生长超声。

局限性

  • 回顾性研究设计,PlGF从储存血清样本中回顾性检测。
  • 单中心或有限中心队列,外推性需进一步验证。
  • 阿司匹林干预可能影响子痫前期患病率,但校正后结果不变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To compare the screening performance of serum pregnancy-associated plasma protein-A (PAPP-A) vs placental growth factor (PlGF) in routine first-trimester combined screening for pre-eclampsia (PE), small-for-gestational age (SGA) at birth and trisomy 21.

METHODS: This was a retrospective study nested in pregnancy cohorts undergoing first-trimester combined screening for PE and trisomy 21 using The Fetal Medicine Foundation (FMF) algorithm based on maternal characteristics, nuchal translucency thickness, PAPP-A, free beta-human chorionic gonadotropin, blood pressure and uterine artery Doppler. Women at high risk for preterm PE (≥ 1 in 50) received 150 mg of aspirin per day, underwent serial fetal growth scans at 28 and 36 weeks and were offered elective birth from 40 weeks of gestation. PlGF was quantified retrospectively from stored surplus first-trimester serum samples. The performance of combined first-trimester screening for PE and SGA using maternal history, blood pressure, uterine artery pulsatility index and either PAPP-A or PlGF was calculated. Similarly, the performance of combined first-trimester screening for trisomy 21 was calculated using either PAPP-A or PlGF in addition to maternal age, nuchal translucency thickness and free beta-human chorionic gonadotropin.

RESULTS: Maternal serum PAPP-A was assayed in 1094 women, including 82 with PE, 111 with SGA (birth weight < 10th centile), 53 with both PE and SGA and 94 with fetal trisomy 21. PlGF levels were obtained retrospectively from 1066/1094 women. Median serum PlGF multiples of the median was significantly lower in pregnancies with PE (1.0 (interquartile range (IQR), 0.8-1.4); P < 0.01), SGA (1.0 (IQR, 0.8-1.3); P < 0.001) and trisomy 21 (0.6 (IQR, 0.5-0.9); P < 0.0001) compared to in controls (1.2 (IQR, 0.9-1.5)). There was no significant difference in the performance of first-trimester screening using PAPP-A vs PlGF for either preterm PE (area under the receiver-operating-characteristics curve (AUC), 0.78 vs 0.79; P = 0.55) or term PE (AUC, 0.74 vs 0.74; P = 0.60). These findings persisted even after correction for the effect of targeted aspirin use on the prevalence of PE. Similarly, there were no significant differences in sensitivity and specificity of combined screening for SGA or trisomy 21 when using PAPP-A vs PlGF.

CONCLUSIONS: Using either PlGF or PAPP-A in routine first-trimester combined screening based on maternal characteristics, blood pressure and uterine artery Doppler does not make a significant clinical difference to the detection of PE or SGA. Depending on the setting, biomarkers should be chosen to achieve a good compromise between performance and measurement requirements. This pragmatic clinical-effectiveness study suggests that combined screening for PE can be implemented successfully in a public healthcare setting without changing current protocols for the assessment of PAPP-A in the first trimester. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Noël L, Guy GP, Jones S, et al. Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor? Ultrasound Obstet Gynecol. 2021. PMID: 33998078. doi:10.1002/uog.23669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。